Subscribe
shutterstock_1414222322_chris_redan
Chris Redan / Shutterstock.com
6 April 2021BiotechnologyClare Roskell and Samantha Moodie

EPO’s new examination guidelines: what you need to know

A new edition of the European Patent Office (EPO) Guidelines for Examination came into force on March 1, 2021. Relevant to life sciences, this edition includes a new subsection detailing EPO practice with respect to the interpretation of terms relating to amino or nucleic acid sequences, as well as a new section on the examination of claims to antibodies.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
Pharma patent filings rise at EPO amid pandemic
5 April 2022   Patent applications in Europe reached record levels during 2021 amid the COVID-19 pandemic, according to a new report by the European Patent Office.
Europe
EPO Enlarged Board of Appeal issues G 2/21 decision
28 March 2023   Board provides guidance on evidence submitted after patent filing date | Eagerly awaited decision confirms what’s needed to prove a certain effect.
Europe
EPO launches Unitary Patent dashboard revealing daily take-up figures
25 July 2023   Interactive statistics chart shows more than 5,000 requests for unitary effect | Data can be filtered by country, language and technology sector.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Europe
Pharma patent filings rise at EPO amid pandemic
5 April 2022   Patent applications in Europe reached record levels during 2021 amid the COVID-19 pandemic, according to a new report by the European Patent Office.
Europe
EPO Enlarged Board of Appeal issues G 2/21 decision
28 March 2023   Board provides guidance on evidence submitted after patent filing date | Eagerly awaited decision confirms what’s needed to prove a certain effect.
Europe
EPO launches Unitary Patent dashboard revealing daily take-up figures
25 July 2023   Interactive statistics chart shows more than 5,000 requests for unitary effect | Data can be filtered by country, language and technology sector.

More on this story

Europe
Pharma patent filings rise at EPO amid pandemic
5 April 2022   Patent applications in Europe reached record levels during 2021 amid the COVID-19 pandemic, according to a new report by the European Patent Office.
Europe
EPO Enlarged Board of Appeal issues G 2/21 decision
28 March 2023   Board provides guidance on evidence submitted after patent filing date | Eagerly awaited decision confirms what’s needed to prove a certain effect.
Europe
EPO launches Unitary Patent dashboard revealing daily take-up figures
25 July 2023   Interactive statistics chart shows more than 5,000 requests for unitary effect | Data can be filtered by country, language and technology sector.

More features

Sanofi subsidiary fends off $450m trade secrets case
Pfizer infringed haemophilia therapy patent, says court
Cooley adds ex-Gowling partner
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
10x Genomics counsel: ‘Winning cases is a top priority’
HR, lobbying and business strategy…all in a day’s work for today’s counsel
LSPN Fall: Gilead GC shares top drafting tips
LSPN Fall: Why Big Pharma is facing 'a balancing act'